We are delighted to announce that Maschio Soames founder and director Dr. Candi Soames will be presenting a keynote speech on IP at the Annual European Antibody Congress in November 2014. The three day conference is now a landmark event in the yearly calendar of the biopharma field and is sure to be well attended. Participants already include global presences GE Healthcare, Novartis, Pfizer, Merck, Roche, Amgen, and Astra Zeneca.
The event provides stakeholders with a one-stop platform to discover what’s new in the field of antibodies and Antibody-Drug Conjugate (ADCs). Topics discussed at previous congress sessions have included ADC therapeutics, bispecifics, characterisation methods, state-of-the-art technologies being developed by the various attendees and Intellectual Property.
This year Candi will be presenting in a plenary session on Intellectual Property considerations when developing antibody and next generation therapeutics. She will be alongside representatives of the European Patent Office and the federal Drug Agency who will also be holding plenary talks to close the congress for this year. The session is likely to be of great interest, as it uniquely brings together intellectual property practitioners, patent granting organisations and regulatory authorities for an exchange of perspectives.
Maschio & Soames IP Limited is committed to this sector and is once again a Gold Sponsor of the Congress. As in previous years, we look forward to meeting colleagues and clients and participating in the stimulating sessions.